Atomo Diagnostics (ASX:AT1): FY26 Revenue, Pascal Platform and Diagnostic Pipeline

Aditi Sarkar

23 October 2026 04:27 PM AEDT

Atomo Diagnostics (ASX:AT1): FY26 Revenue, Pascal Platform and Diagnostic Pipeline

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Atomo Diagnostics (ASX:AT1) reported FY26 revenue of AUD 5.33 million, up 41%.
The FY26 net loss narrowed to AUD 3.51 million from AUD 4.97 million.
HIV-related revenue rose 21% and partner supply revenue increased 209% during FY26.
Atomo finished FY26 with approximately AUD 3.71 million in cash and no debt.

Atomo Diagnostics Limited develops and supplies rapid diagnostic devices and integrated test platforms for use in self-testing and point-of-care healthcare settings. At the time of writing on 23 October 2026, Atomo Diagnostics (ASX:AT1) was quoted at AUD 0.018, up 2.94% for the trading session. The company’s 2026 updates focus on higher annual revenue, commercial supply of its Pascal platform, diagnostic product development and a change in executive leadership.

Company Business

Atomo Diagnostics (ASX:AT1) designs integrated rapid-testing devices combining sample collection, processing and result presentation. Its product activities include HIV self-tests, point-of-care tests and supply of diagnostic cassettes to industry partners. The Pascal platform supports tests developed by other manufacturers, while Atomo also works on its own diagnostic products and customised development services.

The business sells through healthcare and commercial distribution arrangements in Australia, New Zealand, Europe and other international markets. Demand depends on public-health procurement, pharmacy availability, partner manufacturing requirements and regulatory access. Its international operations give the group exposure to varying purchasing cycles, reimbursement arrangements and product registration requirements.

Recent Development

In September 2026, Atomo Diagnostics (ASX:AT1) presented its FY26 results and updated its commercial priorities. Management identified expansion of HIV self-testing, broader Pascal cassette supply and development services as areas of activity. The company also highlighted efforts to improve manufacturing efficiency, including bringing proprietary blister manufacturing processes in-house and using new tooling to manage production costs.

During August 2026, the board appointed existing director Dr Cheri Walker as interim chief executive officer following the departure of managing director John Kelly. The leadership change accompanied a stated intention to focus executive oversight on the company’s international diagnostic markets. Governance and strategy disclosures were subsequently incorporated into its FY26 reporting materials and September investor presentation.

Atomo also advanced work on an active syphilis test and a licensed liver-function diagnostic. Its FY26 materials stated that technical development of the active syphilis test had been completed and transfer toward manufacturing had commenced. These development milestones do not establish regulatory approval or future sales for those products.

Financial Performance and Sector Context

For the year ended 30 June 2026, Atomo Diagnostics (ASX:AT1) reported revenue from ordinary activities of AUD 5,333,849, an increase of 41% from FY25. Its net loss after tax declined to AUD 3,513,587 from AUD 4,970,934 in FY25, representing a 29% reduction. The company remained loss-making despite the improvement in its reported annual result.

The FY26 operational summary recorded HIV-related revenue of approximately AUD 2.8 million, up 21%, and partner supply revenue of approximately AUD 2.2 million, up 209%. These revenue streams reflect different demand channels: purchases of testing products and contracted supply of cassettes used in third-party diagnostic systems. The company reported that its underlying EBITDA loss narrowed by 39%, which differs from statutory net loss and should be assessed separately.

At 30 June 2026, Atomo had approximately AUD 3.71 million of cash and reported no debt. The annual report disclosed capital raising activities during FY26, making both cash expenditure and potential future financing relevant to the company’s financial position. The group’s share base increased over the year, with 902.4 million ordinary shares on issue at year-end compared with 739.1 million at 30 June 2025.

Diagnostic-device demand is influenced by public-health testing budgets, clinical adoption, distribution agreements and regulatory decisions. US CLIA-waived status for a partner’s FebriDx test using Pascal supports one market channel, but commercial volumes ultimately depend on partner orders and end-customer uptake. Regulatory permissions for one product do not automatically provide clearance for other tests.

Risks to Consider

Atomo Diagnostics (ASX:AT1) remains exposed to operating losses, capital requirements and irregular ordering by public-health customers. Pascal sales depend partly on partner product demand and contractual execution. New diagnostic products face technical validation, manufacturing scale-up, regulatory and distribution risks. A limited cash balance relative to ongoing development spending makes working-capital management and the timing of future receipts relevant.

What to Watch Next

The company’s investor calendar identified 30 October 2026 for its Q1 FY27 quarterly activity and cash-flow report, subject to confirmation. That update can provide evidence on receipts, operating payments and available funding. For Atomo Diagnostics (ASX:AT1), other monitoring points include HIV self-test orders, Pascal cassette demand, progress in manufacturing transfer for active syphilis testing and any further product or regulatory updates.

Key Insights

Atomo recorded higher FY26 revenue and a smaller statutory net loss while continuing to spend on commercialisation and product development. HIV testing and diagnostic partner supply contributed to reported sales, and the company ended June 2026 with cash and no debt. For Atomo Diagnostics (ASX:AT1), the next quarterly cash-flow report and execution of existing product and partner arrangements are measurable points for assessing its operating position.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.